Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

556
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
556
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

738
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
738
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

331
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
331

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel.

The British journal of dermatology·2019
Same author

[Susac Syndrome: A Diagnostic Chameleon].

Laryngo- rhino- otologie·2019
Same author

Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Seminars in arthritis and rheumatism·2019
Same author

[Malignant lymphomas of the eye].

Der Pathologe·2017
Same author

[Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis].

Zeitschrift fur Rheumatologie·2017
Same author

Systemic therapy of ocular and cutaneous rosacea in children.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same journal

["DOG 2020 online" - for the first time in the von Graefe year].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2024
Same journal

[Are organ and co-cultures an alternative to animal models in ophthalmology?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Pediatric corneal opacities : Even small improvements provide lifelong help].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Myxoma of the conjunctiva].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Artificial intelligence in the management of anti-VEGF treatment: the Vienna fluid monitor in clinical practice].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.4K

[Therapy of intermediate uveitis].

D Doycheva1, C Deuter, M Zierhut

  • 1Universitäts-Augenklinik Tübingen, Schleichstr. 12-16, 72076, Tübingen, Deutschland, deshka.doycheva@med.uni-tuebingen.de.

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Intermediate uveitis, an eye inflammation primarily affecting the vitreous, is typically managed with systemic corticosteroids. Immunosuppressive drugs or biologics are used for resistant cases or side effects.

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K

Related Experiment Videos

Last Updated: Apr 20, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.4K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K

Area of Science:

  • Ophthalmology
  • Immunology

Context:

  • Intermediate uveitis involves inflammation within the eye, specifically targeting the vitreous.
  • Systemic corticosteroids are the primary medical treatment for this condition.

Purpose:

  • To outline the therapeutic strategies for intermediate uveitis.
  • To discuss alternative treatments when initial therapy fails or causes side effects.

Summary:

  • Corticosteroids are the mainstay for intermediate uveitis, but immunosuppressive agents like Cyclosporine A are crucial for managing recurrences or adverse effects.
  • For severe, refractory cases, biologics offer a treatment option.
  • Intravitreal steroids or vitrectomy may be considered in specific situations, such as unilateral disease or contraindications to systemic therapy.

Impact:

  • Provides a comprehensive overview of intermediate uveitis management.
  • Highlights the role of various immunosuppressive and biologic therapies in optimizing patient outcomes.
  • Informs clinical decision-making for complex cases of intermediate uveitis.